Last reviewed · How we verify
DC AML Vaccine
DC AML Vaccine is a personalized cancer vaccine that targets specific mutations in acute myeloid leukemia.
DC AML Vaccine is a personalized cancer vaccine that targets specific mutations in acute myeloid leukemia. Used for Acute myeloid leukemia (AML).
At a glance
| Generic name | DC AML Vaccine |
|---|---|
| Sponsor | Beth Israel Deaconess Medical Center |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
The vaccine is designed to stimulate the immune system to recognize and attack cancer cells with specific mutations. Each vaccine is tailored to the individual patient's unique mutation profile.
Approved indications
- Acute myeloid leukemia (AML)
Common side effects
- Fatigue
- Chills
- Nausea
- Headache
- Fever
Key clinical trials
- DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission (PHASE2)
- Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML (PHASE1)
- Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients (PHASE1)
- Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission (PHASE2)
- DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML (PHASE1, PHASE2)
- Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission (PHASE2)
- Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid Leukemia (NA)
- Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |